TherapeuticsMD reports Q1 EPS (6c) vs. (7c) last year
Strategic Alternatives Exploration: The Company is assessing various strategic options, including acquisitions, mergers, or asset sales, but there is no guarantee of a successful transaction or outcome.
No Set Timetable for Completion: There is currently no timeline for the exploration process, and the Company will only disclose updates when deemed appropriate or necessary.
Trade with 70% Backtested Accuracy
Analyst Views on TXMD
About TXMD
About the author
Therapeutics MD Reports Improved Financials for FY 2025
- Improved Net Loss: Therapeutics MD reported a net loss from continuing operations of $0.7 million for FY 2025, translating to a loss of $0.06 per basic and diluted share, which is an improvement of $1.7 million compared to a net loss of $2.3 million in FY 2024, indicating positive progress in financial health.
- License Revenue Growth: The company generated $3.0 million in license revenue from continuing operations in FY 2025, an increase of $1.3 million or 71.6% from $1.8 million in FY 2024, primarily driven by increased sales of licensed products under the Mayne License Agreement, showcasing successful market expansion efforts.
- Decrease in Operating Expenses: Total operating expenses for FY 2025 were $7.4 million, down $0.5 million or 5.9% from $7.9 million in FY 2024, mainly due to lower impairment charges recognized in 2025, although this was partially offset by higher bonus expenses and increased investor communication costs.
- Cash Position: As of December 31, 2025, the company reported cash and cash equivalents totaling $7.5 million, indicating a strong liquidity position that supports future operations and investments.
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
TherapeuticsMD Swings to Profit in Q2
Financial Performance: TherapeuticsMD reported a net income of $545 thousand for Q2 2025, a significant improvement from a loss of $1.05 million in the same quarter last year, driven by increased license revenue which rose to $1.0 million and a 45.5% reduction in operating expenses.
Business Model Transition: The company has fully transitioned to a royalty-focused business model, relying on licensing agreements with partners like Mayne Pharma for revenue, while ceasing its own research and development efforts, leading to a focus on cash preservation and operational efficiency.
TherapeuticsMD Q2 Earnings Summary
Earnings Performance: TherapeuticsMD reported earnings of $0.55 million in Q2, a significant improvement from a loss of $1.05 million in the same quarter last year.
Earnings Per Share (EPS): The company achieved an EPS of $0.05 in Q2, compared to a loss of $0.09 per share during the same period last year.
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
GameStop Earnings Report: GameStop Corp. shares rose 13.4% in pre-market trading after reporting fourth-quarter adjusted earnings of 30 cents per share, exceeding analyst expectations, despite revenue falling short of estimates at $1.283 billion.
Pre-Market Stock Movements: Several stocks saw significant gains in pre-market trading, including Theratechnologies Inc. (+88.3%) and SurgePays, Inc. (+69.5%), while others like Golden Heaven Group Holdings Ltd. (-24.4%) and Humacyte, Inc. (-22.1%) experienced notable declines.
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
Market Overview: The Dow Jones index rose over 450 points, indicating positive market sentiment, while insider trading activities in penny stocks reflect investor confidence or concerns regarding company prospects.
Recent Insider Transactions: Notable insider purchases include System1's Cee Holdings Trust acquiring shares after strong earnings, TherapeuticsMD's director buying shares following a quarterly loss, and Ault Alliance's executive purchasing shares amid dividend announcements.
Therapeutics MD Reports Improved Financials for FY 2025
- Improved Net Loss: Therapeutics MD reported a net loss from continuing operations of $0.7 million for FY 2025, translating to a loss of $0.06 per basic and diluted share, which is an improvement of $1.7 million compared to a net loss of $2.3 million in FY 2024, indicating positive progress in financial health.
- License Revenue Growth: The company generated $3.0 million in license revenue from continuing operations in FY 2025, an increase of $1.3 million or 71.6% from $1.8 million in FY 2024, primarily driven by increased sales of licensed products under the Mayne License Agreement, showcasing successful market expansion efforts.
- Decrease in Operating Expenses: Total operating expenses for FY 2025 were $7.4 million, down $0.5 million or 5.9% from $7.9 million in FY 2024, mainly due to lower impairment charges recognized in 2025, although this was partially offset by higher bonus expenses and increased investor communication costs.
- Cash Position: As of December 31, 2025, the company reported cash and cash equivalents totaling $7.5 million, indicating a strong liquidity position that supports future operations and investments.
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
TherapeuticsMD Swings to Profit in Q2
Financial Performance: TherapeuticsMD reported a net income of $545 thousand for Q2 2025, a significant improvement from a loss of $1.05 million in the same quarter last year, driven by increased license revenue which rose to $1.0 million and a 45.5% reduction in operating expenses.
Business Model Transition: The company has fully transitioned to a royalty-focused business model, relying on licensing agreements with partners like Mayne Pharma for revenue, while ceasing its own research and development efforts, leading to a focus on cash preservation and operational efficiency.
TherapeuticsMD Q2 Earnings Summary
Earnings Performance: TherapeuticsMD reported earnings of $0.55 million in Q2, a significant improvement from a loss of $1.05 million in the same quarter last year.
Earnings Per Share (EPS): The company achieved an EPS of $0.05 in Q2, compared to a loss of $0.09 per share during the same period last year.
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
GameStop Earnings Report: GameStop Corp. shares rose 13.4% in pre-market trading after reporting fourth-quarter adjusted earnings of 30 cents per share, exceeding analyst expectations, despite revenue falling short of estimates at $1.283 billion.
Pre-Market Stock Movements: Several stocks saw significant gains in pre-market trading, including Theratechnologies Inc. (+88.3%) and SurgePays, Inc. (+69.5%), while others like Golden Heaven Group Holdings Ltd. (-24.4%) and Humacyte, Inc. (-22.1%) experienced notable declines.
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
Market Overview: The Dow Jones index rose over 450 points, indicating positive market sentiment, while insider trading activities in penny stocks reflect investor confidence or concerns regarding company prospects.
Recent Insider Transactions: Notable insider purchases include System1's Cee Holdings Trust acquiring shares after strong earnings, TherapeuticsMD's director buying shares following a quarterly loss, and Ault Alliance's executive purchasing shares amid dividend announcements.
